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Walshaw [1] in relation to renal disease in cystic fibrosis (CF).
The authors correctly note the use of markers including
neutrophil gelatinase-associated lipocalin (NGAL) and kidney
injury molecule 1 (KIM-1) as indicators of acute kidney injury
(AKI). It is subsequently stated that ‘unfortunately NGAL is also
produced in response to damaged epithelial cells in the lung,
effectively excluding its use in the CF condition.’ However, the
source of this reference, Devarajan [2] makes no such mention of
NGAL in the lung.
There is sparse literature describing NGAL, also known as
lipocalin-2, in the lung. Soni et al. [3] state variable degrees of
NGAL gene expression that is demonstrated in human lung
tissue. The authors describe its role as a growth factor with
elevated levels identified in sputum of patients with asthma and
chronic obstructive airways disease and in the bronchial
secretions from patients with subclinical emphysema. There is
no reference to cystic fibrosis.
A recent study by Zughaier et al. [4] sought to determine
whether NGAL could serve as a maker of acute pulmonary
exacerbation in CF. The study found that serum NGAL levels
were elevated in patients with CF compared to healthy controls.
Although, there was no difference in those with CF and stable
disease compared to those with an exacerbation of CF, it is
acknowledged that this may affect the positive and negative
predictive values of NGAL and the clinical utility of NGAL in
CF, compared to non-CF populations.⁎ Corresponding author at: Infection and Immunity Theme, Murdoch Childrens
Research Institute, 50 Flemington Road, Parkville, Victoria 3052, Australia.
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1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. AWe are unaware of any reason that use of NGAL in CF is
precluded. If NGAL is used as a urinary biomarker to detect renal
impairment, interference with a urinary assay from lung expres-
sion is not expected as NGAL is a large molecule and unlikely to
cross the glomerular barrier. Indeed, one French study (MUCO-
IRC) [5] is currently recruiting patients with CF post lung
transplant and investigating use of NGAL as a biomarker in
chronic renal disease. Until data such as these are available, we
believe it is premature to dismiss the use of NGAL as a marker of
renal dysfunction in CF. Any biomarker with the potential for
early detection of renal dysfunction should be assessed carefully
before dismissing its utility in CF.
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